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CObjectives: To evaluate the long-term cost-effectiveness of switching
from insulin glargine (IGla) to insulin detemir (IDet) in patients with
type 2 diabetes in the setting of Chinese secondary and tertiary
hospitals. Methods: A published and validated computer simulation
odel of diabetes (the Center for Outcomes Research model) was used
o make the long-term (30 years) projection of health economic out-
omes. Patient demographic information and clinical end points were
erived from a subgroup analysis of the Predictable Results and Expe-
ience in Diabetes through Intensification and Control to Target: an
nternational Variability Evaluation (PREDICTIVE) study. Baseline risk
actors and racial characteristic data were obtained from Chinese co-
ort studies. The diabetes management and complications costs were
btained from Chinese published data and adjusted to 2010 values by
sing the Chinese consumer price index. An annual discounting rate of
% was used for both health and cost outcomes, and one-way sensitiv-
ties analysis was performed, which illustrated that the results were O
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doi:10.1016/j.jval.2011.11.018obust. Results: Conversion to IDet from IGla was projected to im-
rove patient life expectancy by 0.06 year and 0.48 quality-adjusted
ife-years. Drug costs and management costs of diabetes mellitus
ere increased by US$368 (US$17,466 vs. US$17,097) and US$31
US$5464 vs. US$5433), respectively. However, the costs of complica-
ions, including cerebrovascular disease, renal complications, ulcer/
mputation/neuropathy, eye complications, and hypoglycemia
vents, were reduced by US$819 (US$21,294 vs. US$22,114), resulting
n a total direct medical cost saving of US$420 when converting to
Det. Conclusions: Conversion to IDet from an IGla regimen improved
ife expectancy andwas a cost-saving treatment approach in a Chinese
etting.
eywords: Chinese setting, cost-effectiveness, cost-utility, insulin det-
mir.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
The effective prevention andmanagement of diabetesmellitus (DM)
is an increasing serious challenge to China. The China National Dia-
betes and Metabolic Disorders Study estimated that the age-stan-
dardizedprevalenceof diabetes andprediabeteswas 9.7%and15.5%,
respectively, accounting for 92.4 million adults with diabetes and
148.2 million adults with prediabetes in China [1]. According to an-
other survey conducted by the Ministry of Health [2], type 2 DM
(T2DM) constitutes about 95%of all patients and the total costs ofDM
inChinawere estimated to be $20.5 billion for 2007,which accounted
for 14.2% of national health-care expenditures [3].
In China, DM-related complications are the key driver of medical
costs. The results of the first national DM-related complications survey
basedonasampleof24,496patientswithdiabetesinChinashowedthat
73.2% of patientswith diabetes had one ormore complications [4]. The
research conducted by Chen et al. [5] revealed that the annual direct
edicalcostofpatientswithcomplicationswas increasedby3.71 times
omparedwith that of thosewithout complications.
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1098-3015/$36.00 – see front matter Copyright © 2012, Internation
Published by Elsevier Inc.In the treatment of DM, insulin plays an important role. Earlier
se of insulin in patients with T2DMwill help to better control the
lucose level and reduce the risk of complications. Detemir and
largine are both long-acting human insulin analogues used for
aintaining the basal level of insulin. They have been proved to
ore closely reflect physiological basal insulin and are associated
ith a significantly less risk of hypoglycemia andweight gain [6,7].
wo pharmacoeconomic studies conducted in Germany [8] and
he United States [9] evaluated the cost-effectiveness of detemir
ased on the clinical results of the German PREDICTIVE study.
oreover, other researches from the United Kingdom [10], Canada
11], and Europe [12] also systematically evaluated the long-term
ealth benefits of detemir caused by the reduction in the hemo-
lobin A1c (Hb A1c) level.
Insulin detemir came to the Chinese market in 2010 and is
eing used in secondary and tertiary hospitals in China. To better
nform the insurance coverage decision makers and the doctors
hether it is value for money in the long run, it is necessary to
ssess the long-term cost-effectiveness of insulin detemir com-
conflicts of interest with regard to the content of this article.
andManagement, School of Public Health, Peking University, No.
ciety for Pharmacoeconomics and Outcomes Research (ISPOR).
f
p
f
v
(
a
t
d
i
T
i
r
t
C
f
a
i
i
i
fl
c
s
a
r
a
S57V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 5 6 – S 5 9pared with that of the existing long-acting human insulin ana-
logues such as insulin glargine.
This studywas conducted to quantify the long-term cost-effec-
tiveness of insulin detemir compared with that of insulin glargine
for the treatment of T2DM in China from a societal perspective,
and to assess the sensitivity of results to disutility values.
Methods
Model
We used a validated computer simulation model of diabetes (the
Center for Outcomes Research [CORE] model) specifically for dia-
betes to convert the short-term clinical effects to long-term eco-
nomic outcomes [13]. Themodel is based on a series of submodels
that simulate the important complications of DM. Each submodel
is a Markovmodel usingMonte Carlo simulation. The COREmodel
takes into account baseline cohort characteristics, history of com-
plications, current and future diabetesmanagement and concom-
itantmedications, screening strategies, and changes in physiolog-
ical parameters over time. The development of complications, life
expectancy, quality-adjusted life-year (QALY), and total costs
within populations can be calculated. Furthermore, the reliability
of simulated outcomes has been tested [13,14].
Treatment effects
The treatment effects were derived from the Korean cohort of the
PREDICTIVE study [15]. In the research, subjects who required
changing treatment, as assessed by their treating physicians, were
transferred to insulin detemir  oral antidiabetic drugs (OADs)
rom insulin glargineOADs. Themajor reasons why the treating
hysicians transferred a patient to insulin detemir included the
ollowing: 1) improve glycemic control (89%); 2) reduce plasma
ariability (53%); 3) patient’s dissatisfaction with current therapy
33%); and 4) improve weight control (29%). Because PREDICTIVE is
n observational study based on everyday clinical practice, the
reating physicians could adjust the patient’s OADs and insulin
etemir dose and frequency for the duration of the study accord-
ng to the patient’s situation.
The subgroup research of the Korean cohort of the PREDIC-
IVE study included 875 patients with T2DM who transferred to
nsulin detemir OADs from insulin glargine OADs. Reported
changes in the Hb A1c level, body mass index (BMI), and hypo-
glycemic event rate were applied in the simulation as shown.
After 3 months of treatment, subjects were associated with a
reduction of 0.20% and 0.12 kg/m2 in the Hb A1c level and BMI,
espectively. The hypoglycemic event rates were lower in pa-
ients using insulin detemir.
Simulation cohort
A hypothetical simulation cohort was generated on the basis of
patient demographics, risk factors, and preexisting complications.
The patient demographics corresponded with the values from the
Korean arm of the PREDICTIVE study [15]. Other data were ex-
tracted from published country-specific articles [16–20] (see Table
1 [Inputs for Chinese simulation cohortwith T2DM] in Supplemen-
tal Materials found at doi:10.1016/j.jval.2011.11.018). We defined
this cohort including 1000 persons.
Costs and perspective
Direct medical costs were accounted from a society perspective
in 2010 US dollars. Direct costs were taken to be the sum of
patients’ management costs and DM-related complications
costs. The costs of lost productivity due to illness and death
were excluded.The management costs and DM-related complications costs
were referred to the results of the survey conducted by the IMS
Health in six tertiary and three secondary hospitals in China [21].
omplication costs refer to medical expenditure that resulted
rom diabetes-related complications. Management costs refer to
dministration devices and blood glucose monitoring and took
nto account OAD usage and variations in insulin dosage as noted
n the PREDICTIVE study. The outpatient visit services and others
ncluding screening services were included. All the costs were in-
ated to 2010 values by using the consumer price index of health
are, which was 3.2% in 2009, 2.9% in 2008, and 2.1% in 2007, re-
pectively [22]. The annual medication costs were calculated and
re shown in Table 2 (Cost data for management and diabetes-
elated complications in China for 2010) in Supplemental Materi-
ls found at doi:10.1016/j.jval.2011.11.018.
Quality of life and utilities
Quality-adjusted life expectancy was incorporated into the analy-
sis by using diabetes-related health state utility and event disutil-
ity values published by Palmer et al. [13]. A disutility value of
0.0035 was applied for eachminor hypoglycemic event (an event
not requiring hospitalization) recorded in the simulation. To cap-
ture the reduced utility associated with major hypoglycemic
events, a disutility value of 0.0118 was applied. Hypoglycemia
disutility values were derived from a published source [23].
Discounting and time horizon
All costs and clinical benefits were discounted at an annual rate of
3.0% in accordance with recommendations by the World Health
Organization [24]. Furthermore, to reflect the chronic nature of
T2DM and capture bothmortality and the incidence of DM-related
complications over patient lifetime, the clinical and economic im-
pact of treatment with insulin detemir was prolonged to 30 years.
Sensitivity analysis
Several one-way sensitivity analyses were performed to examine
the influence of key input parameters on the outcomes projected
by the model. The varying parameters included time horizon (10,
20, or 30 years), discounting rate (0% or 10%), hypoglycemic event
rate (assume same), BMI (assume same), and the reduction in the
Hb A1c level (assume Hb A1c benefits reduced by 50%).
Statistical methodology
A simulated cohort of 1000 patientswas run through themodel 1000
times for each simulation (base-case and sensitivity analysis). The
mean and standard deviation valueswere generated by using a non-
parametric bootstrapping approach. One thousand mean values of
incremental costs and incremental effectiveness in terms of quality-
adjusted life expectancy were plotted on a cost-effectiveness plan.
For treatment that was not dominant, it was planned to generate an
acceptability curve by calculating the proportion of points below a
range of willingness-to-pay threshold.
Willingness to pay
There is no specific threshold to judge the cost-effectiveness of an
intervention in China. According to World Health Organization
recommendations [24], if the incremental costs per effectiveness
are not more than three times the gross domestic product per
capital, the intervention could be regarded as cost-effective. With
gross domestic product per capital for China in 2010 at US$3750,
we used a willingness-to-pay threshold of US$11,250 in this anal-
ysis to determine the likelihood of insulin detemir being consid-
ered cost-effective in China.
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Clinical outcomes
In the base-case analysis, transferring from insulin glargine 
OADs to insulin detemir OADs was associated with an improve-
ent of 0.061 year (11.461 0.176 years vs. 11.522 0.177 years) in
ife expectancy per patient. Maybe it can be attributed to the re-
uction in the Hb A1c level. Capturing the quality of life similarly
showed the benefits of converting to detemir treatment. After
switching to detemir  OADs, the QALYs were increased from
7.457 to 6.974. It was associated with an increment of 0.484 QALYs
per patient (see Table 3 [Summary of base-case results] in Supple-
mental Materials found at doi:10.1016/j.jval.2011.11.018).
Therapy conversion to insulin detemir  OADs from insulin
largineOADswas projected to reduce the cumulative incidence
f eye complications, renal complications, foot complications,
europathic complications, and most of cardiovascular complica-
ions. The most remarkable reduction was found in renal compli-
ations, with 6.37% reduction in end-stage renal complications
see Fig. 1 [Relative changes in the cumulative residence of com-
lications over 30 years] in Supplemental Materials found at doi:
0.1016/j.jval.2011.11.018).
Cost outcomes
Compared with insulin glargine  OADs, treatment with insulin
etemir  OADs was associated with an increase of US$369 in
ifetime drug costs and US$31 in management costs. However, in
he long run, therapy conversion to detemirOADswould reduce
the incidence of DM-related complications,which reducedUS$820
in complication costs. Finally, the higher drug costs and manage-
ment costs of detemirOADsweremore than offset by decreased
omplications costs, giving a net saving of US$420 per patient (see
able 3 [Summary of base-case results] in Supplemental Materials
ound at doi:10.1016/j.jval.2011.11.018).
Evaluation of cost-effectiveness
For patients with T2DM, projection over 30 years indicated that
therapy conversion to insulin detemir  OADs would lower total
treatment costs and increase life expectancy by 0.061 years or
0.484 QALYs per patient. So, we came to the conclusion that
switching patients to treatment with detemir  OADs was the
dominant choice, being cost saving in comparison with glargine
OADs (see Table 3 [Summary of base-case results] in Supplemental
Materials found at doi:10.1016/j.jval.2011.11.018).
The scatter plot that described incremental costs versus incre-
mental effectiveness (in terms of QALY) for insulin detemir 
OADs versus insulin glargine  OADs from the 1000 patients sim-
ulated 1000 times each in the model showed that almost all the
points fell on the right side of the vertical axis. Half of the points
were distributed in the lower right corner quadrant (more effective
and less costly). It meant that insulin detemir  OADs was cost
saving or cost-effective (see Fig. 2 in SupplementalMaterials found
at doi:10.1016/j.jval.2011.11.018).
A cost-effectiveness acceptability curve was generated to eval-
uate the likelihood that insulin detemir  OADs would represent
good value for money in China. At a willingness-to-pay threshold
of US$3750 per QALY gained, insulin detemir  OADs had a 100%
robability of being acceptable compared with insulin glargine 
ADs from a social perspective. At a willingness-to-pay threshold
f US$3750 per life-year gained, insulin detemir  OADs had 65%
robability at least. Even at a willingness-to-pay threshold of zero
er QALY, insulin detemir  OADs still had a 65% likelihood of
eing considered cost-effective (see Fig. 3 in Supplemental Mate-
ials found at doi:10.1016/j.jval.2011.11.018).Sensitivity analysis
A series of sensitivity analysis revealed that the findings in pa-
tients with T2DM were most sensitive to changes in the Hb A1c
level and incidence of all hypoglycemia. Varying time horizons,
discount rate, and BMI had no substantial impact on final results.
Nevertheless, in all the sensitivity analyses undertaken, the incre-
mental cost-effectiveness ratio of insulin detemir  OADs was
lways within the limit of willingness to pay in China (see Table 4
n Supplemental Materials found at doi:10.1016/j.jval.2011.11.018).
In all scenarios of the sensitivity analysis, QALY in patients
reated with insulin detemir  OADs was higher than in patients
treated with insulin glargine  OADs all the time. So, insulin det-
emir  OADs was a cost-saving treatment.
Discussion
Despite the availability of numerous treatment options to reduce
blood glucose levels, the condition of most patients with T2DM in
China was not adequately controlled. Insulin detemir has been
introduced in the Chinese market successfully, which has in-
creased the choice for patients. In consideration of the disease
burden and the current situation of diabetes, however, we should
select the most cost-efficient treatment strategies to control the
increasing costs in this growing population.
Although both insulin detemir and insulin glargine are long-
acting basal insulin, they differ at the molecular level, which may
lead to different treatment effects. The PREDICTIVE study results
not only confirm the difference between thembut also provide the
proof of conversion to detemir treatment after failure of therapy
with glargine. Based on the short-term, patient-based results of
the PREDICTIVE study, long-term projections using the CORE dia-
betes model demonstrated that treatment with insulin detemir 
OADs was associated not only with improvements in life expec-
tancy and QALY in comparison with teatment with insulin
glargineOADs for patients with T2DM but also reduction in total
costs. According to modeling analysis and sensitivity findings,
switching poorly controlled patients to insulin detemir  OADs is
likely to be cost saving in China.
This study is the first to compare the cost-effectiveness of in-
sulin detemir and insulin glargine by applying the CORE model to
the Chinese setting. What is more, this study is not limited to
short-term treatment effects but long-termhealth outcomes. So, it
is very useful for decision makers. It should be noted, however,
that there are some limitations in this research, which must be
pointed out.
First, the CORE model consists of 15 Markov submodels. Every
model will use the probabilities for transitions among different
states. The transition probabilities weremainly derived from clin-
ical trials and epidemiological studies conducted in white cohort.
But medical practice in China has a big gap in comparison with
Western countries. Transition probabilities in China may be
higher than those used in the CORE model. The CORE model is
usedunder Chinesemedical practice,which likely underestimates
the incidence of DM-related complications.
Second, the use of data from the Korean cohort of the PREDIC-
TIVE study to simulate treatment with insulin detemir  OADs in
China inherently carries the assumption that the reported treat-
ment effects are applicable to Chinese patients who share similar
baseline characteristics with those of the Korean cohort and who
are receiving a similarly high level of diabetes care. To overcome
this limitation, it is reassuring that the treatment effects were
varied in the sensitivity analysis. Even though the effect of insulin
detemirOADs treatment on theHbA1c levelwas reduced by 50%,
insulin detemir  OADs treatment was still cost-effective.
Finally, this study considered only the direct costs. The indirect
costs associated with lost productivity were not included. How-
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S59V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 5 6 – S 5 9ever, the indirect costs may account for a large percentage of total
costs. The World Health Organization has noted that most people
with DM in developing countries are middle aged, whereas in de-
veloped nations diabetes predominantly affects patients who
have either left the workforce or are close to retirement [22]. Chan
t al. [23] suggested that the main increase in diabetes prevalence
n Chinawill occur in the 45- to 54-year-old group, during themost
roductive working years. Consequently, the overall benefit of de-
emir may be underestimated in this analysis.
Source of financial support: These findings are the result of
ork supported by the Novo Nordisk (China) Pharmaceuticals Co.,
td. The views expressed in this article are those of the authors.
Conclusion
The findings of this evaluation indicate that therapy conversion to
insulin detemir  OADs in patients with T2DM failing insulin
glargineOADswould be cost saving in China. So, thewidespread
se of detemir will help to reduce the economic burden of the
ation and patients.
Supplemental Materials
Supplemental material accompanying this article can be found in
the online version as a hyperlink at doi:10.1016/j.jval.2011.11.018
or, if a hard copy of article, at www.valueinhealthjournal.com/
issues (select volume, issue, and article).
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